Caesarean Delivery Surgical Site Infection Product Trial:“The CDSSI Trial”

THE ROLE OF IRRISEPT IN REDUCING SURGICAL WOUND INFECTION FOLLOWING CAESAREAN SECTION IN FEDERAL MEDICAL CENTRE, YENAGOA SOUTH- SOUTH NIGERIA

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202203595456214

Enrollment

200

Registered

2022-03-16

Start date

2022-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Site Infection Pregnancy and Childbirth Surgery

Interventions

Caesarean Delivery Surgical Site Infection Product Trial

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Pregnant women booked for elective Caesarean section.

Exclusion criteria

Exclusion criteria: Unbooked patients Patients booked for emergency Caesarean section Obstructed labour Chorioamnionitis Patients being managed for any form of sepsis

Design outcomes

Primary

Measure	Time frame
To reduce CDSSI rates during the 30 days post delivery period when compared retrospectively to the CDSSI rate pre-trial	—

Secondary

Measure	Time frame
The secondary objectives will focus on measuring the reduced length of stay, actual costs associated with CDSSI, and extrapolated costs to the healthcare facility.	—

Countries

Nigeria

Contacts

Public ContactRobert Byron Goodchild

Director Partnerships Development

robertg@InfectionReductionPartners.com+447793547330

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026